Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 73 Results

Title
Intervention Indication Therapeutic Area Year Actions
Canakinumab in addition to pembrolizumab and platinum-based chemotherapy for locally advanced or metastatic non-small-cell lung cancer (NSCLC) Canakinumab (Ilaris; ACZ885) , Pembrolizumab (Keytruda; MK-3475) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2021 View  |  Download
Enfortumab vedotin with pembrolizumab for previously untreated locally advanced or metastatic urothelial cancer Enfortumab vedotin (ASG-22ME; Padcev) , Pembrolizumab (Keytruda; MK-3475) Urothelial cancer Urological Cancer 2022 View  |  Download
Enfortumab vedotin with pembrolizumab for treating bladder cancer Enfortumab vedotin (ASG-22ME; Padcev) , Pembrolizumab (Keytruda; MK-3475) Bladder cancer Urological Cancer 2023 View  |  Download
Lenvatinib and pembrolizumab with transarterial
chemoembolisation for treating hepatocellular
carcinoma
Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2022 View  |  Download
Lenvatinib in addition to everolimus or pembrolizumab for advanced renal cell carcinoma – First line Everolimus (Zortress; RAD001; Afinitor; Certican; RAD-001) , Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475) Renal cell carcinoma (RCC) Renal Cancer 2020 View  |  Download
Lenvatinib in combination with pembrolizumab for advanced endometrial cancer – second line Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475) Endometrial cancer Female Reproductive Cancer 2020 View  |  Download
Lenvatinib in combination with Pembrolizumab for advanced or recurrent endometrial cancer - First Line Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475) Endometrial cancer Female Reproductive Cancer 2021 View  |  Download
Lenvatinib in combination with pembrolizumab for advanced/unresectable hepatocellular carcinoma – first-line Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2021 View  |  Download
Lenvatinib with pembrolizumab for previously treated metastatic non-small cell lung cancer Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2022 View  |  Download
Lenvatinib with pembrolizumab for the treatment of squamous cell carcinoma of the head and neck Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475) Head and neck cancer , Squamous cell carcinoma (SCC) Head and Neck Cancer 2022 View  |  Download
1 2 3 7 8
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications